Heartflow

Platform Engineering Intern (Summer 2027)

Heartflow
Apply
1 day ago
San Francisco, CA, USAIntern
H1B sponsor

Responsibilities

  • Build, scale, and maintain secure cloud infrastructure.
  • Write, review, and deploy infrastructure configurations for scalable and repeatable environments.
  • Design, optimize, and maintain continuous integration and continuous deployment pipelines.
  • Deploy and manage microservices using containerization and orchestration technologies.
  • Improve internal developer tools to increase engineering productivity.
  • Own, implement, and present an end-to-end high-impact summer capstone project.

Requirements

  • Currently pursuing a degree in computer science, software engineering, or a related technical field with an expected graduation date aligned to a 2028 full-time start.
  • Strong understanding of core computer science principles, software engineering fundamentals, and cloud computing concepts.
  • Familiarity with or strong interest in Infrastructure as Code, CI/CD practices, Linux systems, and container orchestration.
  • Strong verbal and written communication skills, including the ability to explain technical concepts and present project findings.
  • Highly motivated, collaborative, and eager to learn from senior engineers.

Benefits

  • 10–12-week Summer 2027 internship.
  • In-person work at Heartflow’s San Francisco office.
  • 1:1 mentorship and daily collaboration with experienced senior platform engineers.
  • Hands-on work supporting AI-driven cardiovascular care products.
  • Potential full-time return offer upon graduation, subject to performance and budget availability.
  • Estimated hourly rate of $45 to $60.

Categories

Heartflow

About Heartflow

501-1,000 employees

HeartFlow develops an AI-driven, non-invasive coronary care platform that converts coronary CT scans into 3D models and physiologic assessments (FFRct), sold to hospitals and cardiology practices. Its HeartFlow One suite (including RoadMap, FFRct, and Plaque Analysis) supports diagnosis and management of coronary artery disease and is cleared for use in the US, UK, Europe, Japan, and Canada. The company is headquartered in San Francisco and is publicly traded on Nasdaq under the ticker HTFL.

Contact me